DelveInsight

DelveInsight A premier Business Consulting and Market Research firm focused exclusively on the healthcare industry

DelveInsight is a cutting-edge market and pipeline analysis and API intelligence knowledge partner for the healthcare sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies. We combine industry expertise with innovation by collecting, analyzing and communicating to deliver critical information to leading decision makers in

the Approved drugs market, Active Pharmaceutical (API) market, Generic market and Drug’s research and development. We help Drug developing companies, Generics and API manufacturing companies to strategize and identify the right thrust areas and potential customers for their existing and new products. The pharmaceuticals market is in its growth stage and we are uniquely positioned to successfully endeavor the dimensions of the fast growing market by providing cutting-edge market and pipeline information, to our clients. Linkedin: https://www.linkedin.com/company/delveinsight-business-research-llp

Ulcerative colitis is a type of inflammatory bowel disease of unknown origin that targets the lining of the colon. As pe...
12/07/2024

Ulcerative colitis is a type of inflammatory bowel disease of unknown origin that targets the lining of the colon. As per DelveInsight analysis, the total ulcerative colitis diagnosed prevalent cases in the 7MM comprised approximately 3 million cases in 2023 and are projected to increase by 2034.

The treatment options for ulcerative colitis vary based on the disease's severity and can be categorized into six main types: conventional therapies, biologics, S1P-receptor modulators, and JAK inhibitors. New mechanisms of action, such as LANCL2 protein stimulators, miR-124 enhancers, TNF-like ligand 1A inhibitors, and toll-like receptor 9 agonists, among others, are expected to broaden the range of available treatments for ulcerative colitis.

Several FDA-approved drugs for treating ulcerative colitis are SIMPONI (Janssen Pharmaceuticals), ENTYVIO (Takeda Pharmaceuticals), Etrasimod (Arena Pharmaceuticals/Pfizer), and SKYRIZI (AbbVie).

The market for ulcerative colitis treatment is highly competitive, with numerous companies such as Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Landos Biopharma, NImmune, Merck, Mesoblast, and others conducting clinical trials to advance treatment options. Promising ulcerative colitis drugs in mid-stage development are expected to enter the market soon, enhancing the ulcerative colitis treatment landscape.

The anticipated launch of these emerging therapies for ulcerative colitis treatment represents a significant advancement in the treatment landscape, promising profound impacts on patient outcomes and quality of life.

Get an in-depth analysis of the top 7 drugs in the ulcerative colitis pipeline at: https://www.delveinsight.com/blog/top-7-drugs-for-ulcerative-colitis-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=kpr

Gummy vitamins have gained significant popularity due to their appealing taste and ease of consumption, making them an a...
10/07/2024

Gummy vitamins have gained significant popularity due to their appealing taste and ease of consumption, making them an attractive alternative to traditional pills. The benefits of gummy vitamins include increased compliance, especially among children and adults who struggle with swallowing pills, and the ability to incorporate a variety of nutrients in a single product. However, there are drawbacks such as higher sugar content and the potential for overconsumption due to their candy-like nature. Market dynamics show a robust growth trajectory driven by rising health awareness and demand for convenient supplement options.

Key players in the market, such as Amway Corporation, Abbott, Glanbia PLC, Bayer AG, Pfizer Inc., Suntory Holdings Ltd, Herbalife Nutrition, Otsuka Holdings Co. Ltd., GlaxoSmithKline PLC, The Bountiful Company, ADM, NU SKIN, Nature's Sunshine Products, Inc., RBK Nutraceuticals, American Health, Good Health New Zealand, International Flavors & Fragrances Inc., NOW Foods, Bionova, Carlyle Nutritionals, LLC, are continuously innovating to improve formulations and cater to diverse consumer needs. As the industry evolves, balancing taste, nutritional value, and safety will be crucial for sustained growth.

Explore the future of gummy vitamins at: https://www.delveinsight.com/blog/pros-and-cons-of-gummy-vitamins?utm_source=blog&utm_medium=promotion&utm_campaign=kpr

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s do...
08/07/2024

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KINSUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. The approval of donanemab solidifies Lilly’s leadership in the Alzheimer’s research and treatment arena.

KISUNLA enters a treatment arena already occupied by LEQEMBI, a similar drug approved. Both medications target the same pathology, but KISUNLA offers a potential advantage – it requires monthly infusions compared to LEQEMBI’s bi-weekly schedule. This could make KISUNLA a more convenient option for patients struggling with the demands of treatment. Donanemab’s approval may prompt a reevaluation of LEQEMBI’s market position and could influence ongoing research and development strategies within the industry.

The Alzheimer’s disease market in the US is projected to grow significantly in the coming years. Numerous partnerships have been established among industry players to expand research efforts and product offerings. Major Key players include AB Science, AC Immune, Novo Nordisk, Novo Nordisk, Biogen, Eisai, Eli Lilly, and AriBio, among others, contributing to evolving market dynamics.

As we celebrate the advancement represented by KISUNLA, it is crucial to continue supporting the diverse needs of all Alzheimer’s patients and their caregivers, ensuring comprehensive care and advancing research for more inclusive and effective treatments.

Get a complete insights on the approval journey of KINSULA at https://www.delveinsight.com/blog/kinsunla-for-alzheimer-disease-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=kpr

Data from the study showed that CD20 CAR-T therapy (MB-106) for BTKi-refractory WM/LPL shows high efficacy and favorable...
26/06/2024

Data from the study showed that CD20 CAR-T therapy (MB-106) for BTKi-refractory WM/LPL shows high efficacy and favorable safety with no grade 3-4 CRS and no grade 2 or higher ICANS. MB-106 has received orphan drug designation by the US FDA for WM, and a multicenter registrational phase II study is currently active in the US for WM.

Unlock Expert Insights and Detailed Analysis through DelveInsight's Premier EHA 2024 Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/mb-106-phase-i-ii-clinical-trial?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

-T

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy f...
26/06/2024

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD). RMAT designation was granted based on robust safety and efficacy data from the ongoing Phase 1 RP-L301 clinical trial and its potential to cure a life-threatening disease for which no curative therapies currently exist.

Unlock In-Depth Expert Insights and Analysis with DelveInsight's Exclusive EHA 2024 Reporting @ https://www.delveinsight.com/eha-conference/eha-2024/rp-l301-phase-i-trial?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

CALQUENCE (acalabrutinib) is a next-generation, selective inhibitor of BTK that binds covalently to BTK, thereby inhibit...
26/06/2024

CALQUENCE (acalabrutinib) is a next-generation, selective inhibitor of BTK that binds covalently to BTK, thereby inhibiting its activity. The drug initially received accelerated approval based on overall response rate in the US in October 2017 for the treatment of adult patients with MCL who have received at least one prior therapy, and later in August 2022 received full approval for the same. Although, now AstraZeneca has been investigating CALQUENCE for earlier use in treatment. However, it is important to note that CALQUENCE is not yet approved for MCL treatment in Japan or the EU.

Unlock In-Depth Expert Insights and Analysis with DelveInsight's Exclusive EHA 2024 Reporting @ https://www.delveinsight.com/eha-conference/eha-2024/calquence-phase-iii-echo-trial?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

Multiple myeloma is a promising therapeutic target due to the widespread expression of BCMA on myeloma cells. The field ...
26/06/2024

Multiple myeloma is a promising therapeutic target due to the widespread expression of BCMA on myeloma cells. The field of BCMA-targeting drugs in multiple myeloma has undergone significant advancement. Introduction of CAR-T cell therapies ABECMA and CARVYKTI, and most recently TECVAYLI, are examples of the rise of the BCMA space in multiple myeloma.

Regeneron’s Linvoseltamab is a BCMAxCD3 bispecific antibody in the pipeline for patients with RRMM. In February 2024, the US FDA accepted for Priority Review the BLA for linvoseltamab for RRMM that has progressed after at least three prior therapies, with a target action date for the FDA decision is August 22, 2024. In addition to this, it is also under review for R/R MM by the EMA with EC decision on the regulatory submission of linvoseltamab for the treatment of adult patients with RRMM is planned for the first half of 2025.

Experience Expert Insights and Comprehensive Analysis with DelveInsight's Special EHA 2024 Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/linvoseltamab-phase-i-ii-linker-mm1-trial?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

J&J dominates the multiple myeloma treatment space by adding two bispecific antibodies approved in the field. TECVAYLI (...
26/06/2024

J&J dominates the multiple myeloma treatment space by adding two bispecific antibodies approved in the field. TECVAYLI (teclistamab) became the first bispecific antibody to get the regulatory nod for treating RRMM in 2022 in the United States and Europe. Later in 2023, TALVEY (talquetamab) and ELREXFIO (elranatamab) were approved for RRMM. Linvoseltamab from Regeneron is also in line to get regulatory nod. In February 2024, the US Food and Drug Administration (FDA) accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with RRMM that has progressed after at least three prior therapies. The target action date for the FDA decision is August 22, 2024.

Experience Expert Insights and Comprehensive Analysis with DelveInsight's Special EHA 2024 Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/cevostamab-phase-i-ii-camma-2?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

GSK's multiple myeloma drug BLENREP (Belantamab Mafodotin/Belamaf), once deemed a failure, is now showing promising pote...
26/06/2024

GSK's multiple myeloma drug BLENREP (Belantamab Mafodotin/Belamaf), once deemed a failure, is now showing promising potential following two significant trial victories. These pivotal results have reignited hopes within the company, with company projections suggesting that BLENREP could achieve peak sales exceeding USD 3 billion.

Unlock the Power of Expert Insights and Thorough Analysis with DelveInsight's EHA 2024 Exclusive Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/blenrep-combo-in-dreamm-7-study?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

The treatment landscape for mantle cell lymphoma is undergoing significant changes, particularly with the introduction o...
26/06/2024

The treatment landscape for mantle cell lymphoma is undergoing significant changes, particularly with the introduction of novel biologically targeted therapies in frontline treatment. These advancements offer new hope for patients, especially those with relapsed or refractory MCL, where options were previously limited.

Historically, older MCL patients have been treated with chemoimmunotherapy regimens like bendamustine and rituximab. However, these treatments often come with significant side effects due to their chemotherapeutic components. The emergence of chemotherapy-free combinations like BOVen (zanubrutinib [BRUKINSA], obinutuzumab [GAZYVA], and venetoclax [VENCLEXTA]) presents a less toxic and potentially more effective alternative for treating older patients with MCL.

Experience Expert Insights and Comprehensive Analysis with DelveInsight's Special EHA 2024 Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/boven-combination-therapy?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

In May 2023, EPKINLY (epcoritamab-bysp) was granted accelerated approval by the US Food and Drug Administration (FDA) fo...
26/06/2024

In May 2023, EPKINLY (epcoritamab-bysp) was granted accelerated approval by the US Food and Drug Administration (FDA) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and high-grade B-cell lymphoma after two or more lines of systemic therapy.

During EHA 2024, Umberto Vitolo reported 1st results from EPCORE NHL-1 FL cycle 1 optimization (C1 OPT) cohort investigating mitigation strategies for cytokine release syndrome (CRS) with no mandatory hospitalization in patients with R/R FL receiving epcoritamab.

Get Ahead with Expert Insights and Full Analysis through DelveInsight's Exclusive EHA 2024 Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/epcoritamab-epcore-nhl-1?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

The development of BI-1206 represents a strategic approach to improving outcomes for patients who are refractory or rela...
26/06/2024

The development of BI-1206 represents a strategic approach to improving outcomes for patients who are refractory or relapse after rituximab treatment. By targeting CD32b, BI-1206 could potentially restore or augment the anti-tumor activity of rituximab, offering a new avenue for patients who have limited options due to resistance. BI-1206 in combination with rituximab appears to be safe and adverse drug reactions are manageable. Subcutaneous administration shows great potential to mitigate TEAEs further, and to provide prolonged target engagement with increased patient convenience.

Unlock the Power of Expert Insights and Thorough Analysis with DelveInsight's EHA 2024 Exclusive Coverage @ https://www.delveinsight.com/eha-conference/eha-2024/bi-1206-phase-i-iia-clinical-trial?utm_source=eha&utm_medium=promotion&utm_campaign=kpr

Address

428, Corporate Park, Sector-21, Dwarka, New
Delhi
110077

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Website

Alerts

Be the first to know and let us send you an email when DelveInsight posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to DelveInsight:

Shortcuts

Share